Open-label phase II clinical trial of ketoconazole as CYP17 inhibitor in metastatic or advanced non-resectable granulosa cell ovarian tumors: the GREKO (GRanulosa Et KetOconazole) trial, GETHI 2011-03

被引：0
|
作者：
Jesus Garcia-Donas
Alicia Hurtado
Laia Garrigos
Ana Santaballa
Andres Redondo
Laura Vidal
Nuria Lainez
Eva Guerra
Victor Rodriguez
Juan Cueva
Isabel Bover
Isabel Palacio
Maria Jesus Rubio
Mario Prieto
Jose Antonio Lopez-Guerrero
Juan Francisco Rodriguez-Moreno
Zaida Garcia-Casado
Elena Garcia-Martinez
Alvaro Taus
Ignacio Pérez de Castro
Paloma Navarro
Enrique Grande
机构：
[1] HM Hospitales—Centro Integral Oncológico HM Clara Campal,Institute of Rare Diseases Research
[2] Hospital Universitario Fundación Alcorcón,undefined
[3] Hospital Universitario del Mar,undefined
[4] Hospital Universitario La Fe,undefined
[5] Hospital Universitario La Paz,undefined
[6] Hospital Universitario Clinico de Barcelona,undefined
[7] Hospital de Navarra,undefined
[8] Hospital Universitario Ramon y Cajal,undefined
[9] Hospital Universitario Valle Ebron,undefined
[10] Complexo Hospital Universitario de Santiago de Compostela,undefined
[11] Hospital Universitario Son Llatzer,undefined
[12] Hospital Central de Asturias,undefined
[13] Hospital Universitario Reina Sofía,undefined
[14] Fundacion Instituto Valenciano de Oncología,undefined
[15] Hospital General Universitario Morales Meseguer,undefined
[16] Instituto de Salud Carlos III,undefined
[17] Anderson Cancer Center,undefined
来源：
Clinical and Translational Oncology | 2023年 / 25卷
关键词：
Granulosa cell ovarian cancer; Ketoconazole; Hormonetherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2090 / 2098
页数：8
相关论文
共 12 条
  • [1] Open-label phase II clinical trial of ketoconazole as CYP17 inhibitor in metastatic or advanced non-resectable granulosa cell ovarian tumors: the GREKO (GRanulosa Et KetOconazole) trial, GETHI 2011-03
    Garcia-Donas, Jesus
    Hurtado, Alicia
    Garrigos, Laia
    Santaballa, Ana
    Redondo, Andres
    Vidal, Laura
    Lainez, Nuria
    Guerra, Eva
    Rodriguez, Victor
    Cueva, Juan
    Bover, Isabel
    Palacio, Isabel
    Rubio, Maria Jesus
    Prieto, Mario
    Lopez-Guerrero, Jose Antonio
    Rodriguez-Moreno, Juan Francisco
    Garcia-Casado, Zaida
    Garcia-Martinez, Elena
    Taus, Alvaro
    de Castro, Ignacio Perez
    Navarro, Paloma
    Grande, Enrique
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2023, 25 (07): : 2090 - 2098
  • [2] Open-label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced non-resectable granulosa cell ovarian tumors: the Greko II study (GETHI2013-01)
    Garcia-Donas, Jesus
    Garrigos, Laia
    Lainez, Nuria
    Santaballa, Ana
    Redondo, Andres
    Cueva, Juan Fernando
    Rubio, M. Jesus
    Prieto, Mario
    Lopez-Guerrero, Jose Antonio
    Garcia-Casado, Zaida
    Barquin, Aranzanzu
    Grande, Enrique
    Alia, Eva Guerra
    Sevillano, Elena
    Bover, Isabel
    Grazioso, Tatiana P.
    Sanchez-Escribano, Ramon
    Hurtado, Alicia
    Navarro, Paloma
    Rodriguez-Moreno, Juan Francisco
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024,
  • [3] Ketoconazole as inhibitor of the enzyme CYP17 in locally advanced or disseminated granulosa cell tumors of the ovary (the GreKo I study) (gethi 11-03).
    Garrigos, Laia
    Hurtado, Alicia
    Santaballa, Ana
    Redondo, Andres
    Lainez, Nuria
    Vidal Boixader, Laura
    Guerra Alia, Eva
    Rodriguez, Victor
    Fernando Cueva, Juan
    Bover, Isabel
    Palacio, Isabel
    Jesus Rubio, M.
    Prieto, Mario
    Antonio Lopez-Guerrero, Jose
    Romero, Nuria
    Garcia-Casado, Zaida
    Garcia-Martinez, Elena
    Grande, Enrique
    Garcia-Donas, Jesus
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [4] Open label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced non-resectable granulosa cell ovarian tumors: The Greko II study-GETHI 2013-01.
    Rodriguez-Moreno, Jf.
    Garcia-Donas, Jesus
    Garrigos, Laia
    Lainez, Nuria
    Santaballa, Ana
    Redondo, Andres
    Fernando Cueva, Juan
    Jesus Rubio, Maria
    Hernando Polo, Susana
    Bover, Isabel
    Palacio, Isabel
    Garcia-Casado, Zaida
    Grande, Enrique
    Hurtado, Alicia
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [5] Open label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced non-resectable granulosa cell ovarian tumors: The Greko II study.
    Garcia-Donas, Jesus
    Garrigos, Laia
    Lainez, Nuria
    Santaballa, Ana
    Redondo, Andres
    Cueva, Juan Fernando
    Rubio, M. Jesus
    Prieto, Mario
    Lopez-Guerrero, Jose Antonio
    Garcia-Casado, Zaida
    Grande, Enrique
    Alia, Eva Guerra
    Bover, Isabel
    Polo, Susana Hernando
    Sanchez-escribano, Ricardo
    Hurtado, Alicia
    Navarro, Paloma
    Rodriguez-Moreno, Juan Francisco
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [6] Phase II clinical trial assessing the efficacy of enzalutamide in advanced non-resectable granulosa cell ovarian tumors: The GREKO III study (GETHI2016-01)
    Garcia-Donas, Jesus
    Redondo, Andres
    Santaballa, Ana
    Garrigos, Laia
    Rubio, M. Jesus
    Lainez, Nuria
    Gonzalez, Maria Iglesias
    Cueva, Juan Fernando
    Barquin, Arantzazu
    Grazioso, Tatiana P.
    Hurtado, Alicia
    Sevillano, Elena
    Grande, Enrique
    Rodriguez-Moreno, Juan Francisco
    Navarro, Paloma
    GYNECOLOGIC ONCOLOGY, 2024, 191 : 233 - 239
  • [7] Open-label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced nonresectable granulosa cell ovarian tumors: The GREKO II study.
    Hurtado, Alicia
    Garcia-Donas, Jesus
    Garrigos, Laia
    Lainez, Nuria
    Redondo, Andres
    Fernando Cueva, Juan
    Santaballa, Ana
    Jesus Rubio, Maria
    Palaclo, Isabel
    Bover, Isabel
    Antonio Lopez-Guerrero, Jose
    Prieto, Mario
    Garcia-Casado, Zaida
    Hernando Polo, Susana
    Romero, Nuria
    Grande, Enrique
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] Open-label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced nonresectable granulosa cell ovarian tumors: The GREKO II study.
    Garrigos, Laia
    Santaballa, Ana
    Hurtado, Alicia
    Rodriguez-Moreno, Juan Francisco
    Sanchez-escribano, Ricardo
    Redondo, Andres
    Lainez, Nuria
    Rubio, M. Jesus
    Bover, Isabel
    Cueva, Juan Fernando
    Polo, Susana Hernando
    Manuel, Marta Izquierdo
    Prieto, Mario
    Lopez-Guerrero, Jose Antonio
    Garcia-Casado, Zaida
    Perez, Ignacio
    De Las Penas, Ramon
    Grande, Enrique
    Garcia-Donas, Jesus
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [9] Cisplatin/5-FU (CF) +/ panitumumab (P) for patients (pts) with non-resectable, advanced, or metastatic esophageal squamous cell cancer (ESCC): An open-label, randomized AIO/TTD /BDGO/EORTC phase III trial (POWER).
    Moehler, Markus H.
    Thuss-Patience, Peter C.
    Brenner, Baruch
    Longo, Federico
    Meiler, Johannes
    Ettrich, Thomas Jens
    Hofheinz, Ralf
    Al-Batran, Salah-Eddin
    Vogel, Arndt
    Mueller, Lothar
    Lutz, Manfred P.
    Borchert, Kersten
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER)
    Moehler, M.
    Maderer, A.
    Thuss-Patience, P. C.
    Brenner, B.
    Meiler, J.
    Ettrich, T. J.
    Hofheinz, R-D
    Al-Batran, S. E.
    Vogel, A.
    Mueller, L.
    Lutz, M. P.
    Lordick, F.
    Alsina, M.
    Borchert, K.
    Greil, R.
    Eisterer, W.
    Schad, A.
    Slotta-Huspenina, J.
    Van Cutsem, E.
    Lorenzen, S.
    ANNALS OF ONCOLOGY, 2020, 31 (02) : 228 - 235
12